FDA Brief

Warning letters Drugs

FDA warning letter to

Chongqing Qiancan Technology Co., Ltd.

High riskIssued Oct 29Posted Nov 10Center for Drug Evaluation and Research (CDER)

Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

What happened

FDA reviewed import records showing multiple shipments of active pharmaceutical ingredients (APIs, the working drug substances) for prescription compounding into the U.S. that named Chongqing Qiancan Technology (CQT) as the manufacturer. FDA emailed a records request on June 17, 2026; the firm de-registered and stopped its drug listing on June 29, replied on June 30 saying it could not meet FDA requirements, and never sent the records, though its APIs were still in the U.S. and within expiry. The firm re-registered on July 13, 2026, and FDA placed all its drugs offered for import on Import Alert 66-79 on August 26, 2026.

What FDA found

  1. The firm refused to give FDA records it asked for about drugs it made for the U.S. market.

    Section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4); prohibited act under section 301(e), 21 U.S.C. 331(e)
  2. The firm cancelled its registration and drug listing one day before replying, then re-registered two weeks later, while its APIs were still in the U.S. and within expiry.

  3. Because no records were provided, FDA has no information on the level of quality assurance for drugs made at the site.

What FDA wants

Send a written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receiving the letter, marked with FEI 3040333997 and ATTN: Marva Taylor. The firm may also ask FDA to schedule an inspection.

Who should pay attention

  • compounding pharmacies and other buyers of APIs for prescription compounding
  • U.S. importers and distributors of APIs made in China
  • drug makers whose products use APIs from this site

This is a summary. Read the original letter on fda.gov.